Buprenorphine treatment for narcotic addiction: Not without risks

Innovations in Clinical Neuroscience

Volumn 12, Issue 3-4, 2015, Pages 32-36

  Sansone, Randy A ^a,b   Sansone, Lori A ^c  

^a WRIGHT STATE UNIVERSITY   (United States)

^b KETTERING MEDICAL CENTER   (United States)

^c WRIGHT PATTERSON AIR FORCE BASE   (United States)

Author keywords

Buprenorphine; Buprenorphine naloxone; Naloxone; Narcotics; Opiate addiction; Opiates; Opioid addiction; Opioids

Indexed keywords

BUPRENORPHINE; METHADONE; NALOXONE;

ARTICLE; AUSTRALIA; COUNSELING; DEATH; DRUG ABUSE; DRUG MISUSE; EUROPE; HEALTH PROGRAM; HUMAN; NEW ZEALAND; OPIATE ADDICTION; RISK ASSESSMENT;

EID: 84938086050     PISSN: 21588333     EISSN: 21588341     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. US Department of Health and Human Services. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Located at: http://buprenorphine.samhsa.gov/Bu p_Guidelines.pdf. Accessed on January 22, 2014
2. Gold Standard, Inc. Buprenorphine. Clinical Pharmacology [database online]. http://www.clinicalpharmacology.com. Accessed on 1/22/14
3. Stimmel B. Buprenorphine misuse, abuse, and diversion: when will we ever learn? J Addict Dis. 2007;26:1–3
4. BupPractice. Physician requirements to prescribe buprenorphine. http://www.buppractice.com/node/4335. Accessed on January 27, 2014
5. No authors listed. Buprenorphine replacement therapy: a confirmed benefit. Prescrire Int. 2006;15:64–70
6. Ling W. Buprenorphine for opioid dependence. Expert Rev Neurother. 2009;9:609–616
7. Mammen K, Bell J. The clinical efficacy and abuse potential of combination of buprenorphinenaloxone in the treatment of opioid dependence. Expert Opin Pharmacother. 2009;10:2537–2544
8. Comer SD, Sullivan MA, Vosburg SK, et al. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroine abusers. Addiction. 2010;105:709–718
9. Middleton LS, Nuzzo PA, Lofwall MR, et al. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction. 2011;106:1460–1473
10. Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev. 2011;4:28–41
11. Wish ED, Artigiani E, Billing A, et al. The emerging buprenorphine epidemic in the United States. J Addict Dis. 2012;31:3–7
12. Pauly V, Pradel V, Pourcel L, et al. Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France. Drug Alcohol Depend. 2012;126:13–20
13. Lapeyre-Mestre M, Damase-Michel C, Adams P, et al. Falsified or forged medical prescriptions as an indicator of pharmacodependence: a pilot study. Community pharmacists of the Midi-Pyrenees. Eur J Clin Pharmacol. 1997;52:37–39
14. Claudon-Charpentier A, Hoibian M, Glasser P, et al. Drug-addicted prisoners: seroprevalence of human immunodeficiency virus and hepatitis B and C virus soon after the marketing of buprenorphine. Rev Med Interne. 2000;21:505–509
15. Obadia Y, Perrin V, Feroni I, et al. Injecting misuse of buprenorphine among French drug users. Addiction. 2001;96:267–272
16. Vidal-Trecan G, Varescon I, Nabet N, Biossonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend. 2003;69:175–181
17. Roux P, Villes V, Blanche J, et al. Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management. Drug Alcohol Depend. 2008;97:105–113
18. Aalto M, Halme J, Visapaa J-P, Salaspuro M. Buprenorphine misuse in Finland. Subst Use Misuse. 2007;42:1027–1028
19. Hakansson A, Medvedeo A, Andersson M, Berglund M. Buprenorphine misuse among heroin and amphetamine users in Malmo, Sweden: purpose of misuse and route of administration. Eur Addict Res. 2007;13:207–215
20. Kufner H, Rosner S. Monitoring of the misuse of prescription drugs by clients of outpatient addiction treatment centers (PHAR-MON, formerly Ebis-med). Monitoring of medication misuse. Gesundheitswesen. 2008;70:305–314
21. Moratti E, Kashanpour H, Lombardelli T, Maisto M. Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy. Clin Drug Investig. 2010;30:S3–11
22. Casati A, Sedefov R, Pfeiffer- Gerschel T. Misuse of medicines in the European Union: a systematic review of the literature. Eur Addict Res. 2012;18:228–245
23. Robinson GM, Dukes PD, Robinson BJ, et al. The misuse of buprenorphine and a buprenorphinenaloxone combination in Wellington, New Zealand. Drug Alcohol Depend. 1993;33:81–86
24. Jenkinson RA, Clark NC, Fry CL, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction. 2005;100:197–205
25. Nielsen S, Dietze P, Dunlop A, et al. Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified. Drug Alcohol Rev. 2007;26:143–151
26. Winstock AR, Lea T. Diversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales, Australia. Subst Use Misuse. 2010;45:240–252
27. Smirnov A, Kemp R. Use and misuse of opioid replacement therapies: a Queensland study. Subst Use Misuse. 2012;47:78–85
28. Cicero TJ, Surratt HL, Inciardi J. Use and misuse of buprenorphine in the management of opioid addiction. J Opioid Manag. 2007;3:302–308
29. Monte AA, Mandell T, Wilford BB, et al. Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. J Addict Dis. 2009;28:226–231
30. Schuman-Olivier Z, Albanese M, Nelson SE, et al. Self-treatment: illicit buprenorphine use by opioiddependent treatment seekers. J Subst Abuse Treat. 2010;39:41–50
31. Bazazi AR, Yokell M, Fu JJ, et al. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. J Addict Med. 2011;5:175–180
32. Daniulaityte R, Falck R, Carlson RG. Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids. Drug Alcohol Depend. 2012;122:201–207
33. Gwin Mitchell S, Kelly SM, Brown BS, et al. Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. Am J Addict. 2009;18:346–355
34. Cazorla C, Grenier de Cardenal D, Schuhmacher H, et al. Infectious complications and misuse of highdose buprenorphine. Presse Med. 2005;34:719–724
35. Dasgupta N, Bailey EJ, Cicero T, et al. Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Med. 2010;11:1078–1091
36. Centers for Disease Control and Prevention. Buprenorphine prescribing practices and exposures reported to a poison center-Utah, 2002-2011. MMWR Morb Mortal Wkly Rep. 2012;61:997–1001
37. Bell JR, Butler B, Lawrance A, et al. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend. 2009;104:73–77
38. Pelissier-Alicot AL, Sastre C, Baillif- Couniou V, et al. Buprenorphinerelated deaths: unusual forensic situations. Int J Legal Med. 2010;124:647–651
39. Megarbane B, Hreiche R, Pirnay S, et al. Does high-dose buprenorphine cause respiratory depression? Possible mechanisms and therapeutic consequences. Toxicol Rev. 2006;25:79–85
40. Selden T, Ahlner J, Druid H, Kronstrand R. Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome. Forensic Sci Int. 2012;220:284–290
41. Reynaud M, Petit G, Potard D, Courty P. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction. 1998;93:1385–1392
42. Reynaud M, Tracqui A, Petit G, et al. Six deaths linked to misuse of buprenorphine-benzodiazepine combinations. Am J Psychiatry. 1998;155:448–449.